Regencell Bioscience Asia aims to be the global leader in the research, development and commercialization of Traditional Chinese Medicine (“TCM”) for the treatment of the coronavirus disease particularly COVID-19, for which there are unmet holistic medical needs in the global market.
Regencell Bioscience Asia aims to be the global leader in the research, development and commercialization of Traditional Chinese Medicine (“TCM”) for the treatment of the coronavirus disease particularly COVID-19, for which there are unmet holistic medical needs in the global market.
Our primary goal is to save lives.
We expect to offer COVID-19 related TCM treatments to patients in ASEAN countries, including India, Japan, Australia and New Zealand.
Our primary goal is to save lives.
We expect to offer COVID-19 related TCM treatments to patients in ASEAN countries, including India, Japan, Australia and New Zealand.
As COVID-19 vaccination rates in the Asian region are still low while COVID-19 infections and deaths rates are rising rapidly, a widely available and easily accessible treatment given early during infection will be the most effective way to eliminate symptoms, recover, (negative RT-PCR test results), lower hospitalization and mortality rates and relief long-term health effects associated with COVID-19 (long-COVID).
As COVID-19 vaccination rates in the Asian region are still low while COVID-19 infections and deaths rates are rising rapidly, a widely available and easily accessible treatment given early during infection will be the most effective way to eliminate symptoms, recover, (negative RT-PCR test results), lower hospitalization and mortality rates and relief long-term health effects associated with COVID-19 (long-COVID).
Regencell Bioscience Asia Limited
Malaysia
03-01, Vida Bukit Ceylon,
No. 1D Jalan Ceylon,
50200 Kuala Lumpur
Hong Kong
9/F Chinachem Leighton Plaza
29 Leighton Road
Causeway Bay, Hong Kong